These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23487168)

  • 41. [Therapeutic interchange standardization for antiotensin II receptor antagonists in the treatment of hypertension in the hospital setting].
    Porta Oltra B; Borrás Almenar C; Jiménez Torres NV
    Farm Hosp; 2005 Mar; 29(2):104-12. PubMed ID: 16013932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multivalent nanoparticles bind the retinal and choroidal vasculature.
    Hennig R; Ohlmann A; Staffel J; Pollinger K; Haunberger A; Breunig M; Schweda F; Tamm ER; Goepferich A
    J Control Release; 2015 Dec; 220(Pt A):265-274. PubMed ID: 26494258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects.
    Miura S; Karnik SS; Saku K
    J Renin Angiotensin Aldosterone Syst; 2011 Mar; 12(1):1-7. PubMed ID: 20603272
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Divergent Spatiotemporal Interaction of Angiotensin Receptor Blocking Drugs with Angiotensin Type 1 Receptor.
    Singh KD; Unal H; Desnoyer R; Karnik SS
    J Chem Inf Model; 2018 Jan; 58(1):182-193. PubMed ID: 29195045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiotensin II receptor antagonists (AT
    van Zwieten PA
    Neth Heart J; 2006 Nov; 14(11):381-387. PubMed ID: 25696573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin receptor blockers and drug-drug interactions.
    Sica DA
    Expert Opin Drug Saf; 2005 Jan; 4(1):139-40. PubMed ID: 15709904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular docking, molecular dynamics, and
    Alnajjar R; Mostafa A; Kandeil A; Al-Karmalawy AA
    Heliyon; 2020 Dec; 6(12):e05641. PubMed ID: 33294721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rational Design and Synthesis of AT1R Antagonists.
    Georgiou N; Gkalpinos VK; Katsakos SD; Vassiliou S; Tzakos AG; Mavromoustakos T
    Molecules; 2021 May; 26(10):. PubMed ID: 34069122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography.
    Zhang H; Unal H; Gati C; Han GW; Liu W; Zatsepin NA; James D; Wang D; Nelson G; Weierstall U; Sawaya MR; Xu Q; Messerschmidt M; Williams GJ; Boutet S; Yefanov OM; White TA; Wang C; Ishchenko A; Tirupula KC; Desnoyer R; Coe J; Conrad CE; Fromme P; Stevens RC; Katritch V; Karnik SS; Cherezov V
    Cell; 2015 May; 161(4):833-44. PubMed ID: 25913193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
    Byrd JB; Chertow GM; Bhalla V
    N Engl J Med; 2019 Apr; 380(17):1589-1591. PubMed ID: 30865819
    [No Abstract]   [Full Text] [Related]  

  • 51. Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool.
    Lim TM; Ibrahim MI
    Pharm Pract (Granada); 2012 Jul; 10(3):136-42. PubMed ID: 24155829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage.
    Horiuchi M; Mogi M
    Br J Pharmacol; 2011 Jul; 163(6):1122-30. PubMed ID: 21175580
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proposed new score to rate the strength of evidence and its application to large-scale clinical trials of angiotensin-receptor blockers.
    Yamazaki T
    Circ J; 2006 Sep; 70(9):1155-8. PubMed ID: 16936428
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New insights into the management of hypertension and cardiovascular risk with Angiotensin receptor blockers: observational studies help us?
    Goudev A
    Open Cardiovasc Med J; 2014; 8():35-42. PubMed ID: 24847388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.
    Vauquelin G; Van Liefde I; Swinney DC
    Br J Pharmacol; 2016 Apr; 173(8):1268-85. PubMed ID: 26808227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Models and methods for studying insurmountable antagonism.
    Vauquelin G; Van Liefde I; Vanderheyden P
    Trends Pharmacol Sci; 2002 Nov; 23(11):514-8. PubMed ID: 12413806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.
    Zaiken K; Hudd TR; Cheng JW
    Ann Pharmacother; 2013 May; 47(5):686-93. PubMed ID: 23585649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy.
    Angeloni E
    Core Evid; 2016; 11():1-10. PubMed ID: 27103882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Angiotensin receptor blockers - advantages of the new sartans.
    Sabbah ZA; Mansoor A; Kaul U
    J Assoc Physicians India; 2013 Jul; 61(7):464-70. PubMed ID: 24772750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes.
    Abdelsaid M; Coucha M; Ergul A
    Transl Res; 2014 Nov; 164(5):424-32. PubMed ID: 24999268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.